Calendrier des promotions Aladdin Healthcare Technologies SE
Calendrier avancé
Graphique simple
À propos de l'entreprise
Aladdin Healthcare Technologies SE, through its subsidiary, Aladdin Healthcare Technologies Ltd, develops software solutions for the storage and management of health information using blockchain technology. The company provides Artificial Intelligence assisted Drug Discovery platform to identify various small molecule drug compounds with multiple age-related diseases, including Alzheimer's, Parkinson's, and SARS-CoV-2; PharmaKG, a biomedical knowledge graph; and Disease Diagnosis and Risk Assessment Platform. The company was founded in 2014 and is based in Berlin, Germany.
| Changement de prix par jour: |
+0% (0.014) |
| Changement de prix par semaine: |
+0% (0.014) |
| Changement de prix par mois: |
+0% (0.014) |
| Changement de prix sur 3 mois: |
+0% (0.014) |
| Changement de prix sur six mois: |
+0% (0.014) |
| Changement de prix par an: |
+0% (0.014) |
| Evolution du prix sur 3 ans: |
-95.41% (0.305) |
| Evolution du prix sur 5 ans: |
+0% (0.014) |
| Evolution des prix sur 10 ans: |
+0% (0.014) |
| Evolution des prix depuis le début de l'année: |
+0% (0.014) |
|
|
Sous-estimation
| Nom |
Signification |
Grade |
| P/S |
0 |
0 |
| P/BV |
0 |
0 |
| P/E |
0 |
0 |
| EV/EBITDA |
0 |
0 |
| Total: |
|
2.5 |
|
Efficacité
| Nom |
Signification |
Grade |
| ROA, % |
0 |
0 |
| ROE, % |
0 |
0 |
| Total: |
|
0 |
|
|
|
Dividendes
| Nom |
Signification |
Grade |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| Total: |
|
0 |
|
Devoir
| Nom |
Signification |
Grade |
| Debt/EBITDA |
0 |
10 |
| Total: |
|
10 |
|
Impulsion de croissance
| Nom |
Signification |
Grade |
| Rentabilité Revenue, % |
0 |
0 |
| Rentabilité Ebitda, % |
1264.44 |
10 |
| Rentabilité EPS, % |
-108.92 |
0 |
| Total: |
|
6 |
|
| Superviseur |
Titre d'emploi |
Paiement |
Année de naissance |
| Mr. Wade Menpes-Smith |
Chairman of the Board, CEO & MD |
|
|
| Mr. Bimal Shah |
Deputy Chairman & COO |
|
|
| Mr. Hamish Badenoch |
CFO & Director |
|
|
| Prof. David C. Rubinsztein |
Member of Drug Discovery Advisory Board & Chief Scientific Advisor |
|
|
| Mr. Paul Sitoh |
Head of Blockchain Technology |
|
|
